Abbott Laboratories (ABT)

Debt-to-assets ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	13,599,000	14,477,000	14,562,000	14,615,000	14,522,000	15,297,000	16,755,000	17,086,000	17,296,000	17,446,000	17,547,000	17,489,000	18,527,000	18,349,000	18,184,000	16,804,000	16,661,000	17,639,000	18,982,000	18,845,000
Total assets	US$ in thousands	73,214,000	72,090,000	73,354,000	73,794,000	74,438,000	72,801,000	74,202,000	74,007,000	75,196,000	73,795,000	73,269,000	72,785,000	72,548,000	69,043,000	68,776,000	66,777,000	67,887,000	68,539,000	68,427,000	67,610,000
Debt-to-assets ratio		0.19	0.20	0.20	0.20	0.20	0.21	0.23	0.23	0.23	0.24	0.24	0.24	0.26	0.27	0.26	0.25	0.25	0.26	0.28	0.28

December 31, 2023 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $13,599,000K ÷ $73,214,000K
= 0.19

The debt-to-assets ratio for Abbott Laboratories has been relatively stable over the past eight quarters, ranging from 0.20 to 0.23. This indicates that Abbott Laboratories finances a small portion of its assets through debt, with the majority of its assets being funded by equity. A lower debt-to-assets ratio suggests lower financial risk and greater financial stability as the company is not overly reliant on debt to finance its operations. However, it is essential to monitor this ratio over time to ensure that the company's debt levels remain manageable and in line with industry benchmarks.